Aims: To evaluate dose levels for semaglutide, a glucagon-like peptide-1 analogue approved for the treatment of type 2 diabetes, by examining the effects of demographic factors on efficacy and safety in an exposure-response analysis.
population subsets, particularly those expected to have exposures at the low and high extremes, such as high vs low body weight, which has been shown to be of importance for semaglutide exposure. 7 In the exposure-response analyses, we aimed to evaluate the efficacy and safety/tolerability of semaglutide across a broad range of exposures generated from four trials in the clinical development programme with semaglutide doses 0.5 and 1.0 mg. [8] [9] [10] [11] We wanted to determine if all subgroups of patients would obtain effective exposure levels with a semaglutide 0.5 mg dose, and if meaningful additional benefits could be obtained with the higher 1.0 mg dose.
| METHODS

| Trials providing data for exposure-response analyses
The exposure-response analyses included data from 1423 adults randomized to semaglutide in four trials from the semaglutide SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) programme [8] [9] [10] [11] (Table S1) , and from 129 adults randomized to placebo (SUSTAIN 1). The trials investigated semaglutide doses 0.5 and Table S1 ).
Three trials were global and one was conducted in Japan (Clinicaltrials.gov identifiers: NCT02054897, NCT01930188, NCT01885208 and NCT02207374). [8] [9] [10] [11] The trials enrolled men and women diagnosed with T2DM; in the global trials participants were aged ≥18 years and in the trial from Japan they were aged ≥20 years.
No restrictions on body weight or body mass index (BMI) applied.
Detailed enrolment criteria have been published previously.
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| Data sets for exposure-response analyses
The data were from participants who had both pharmacokinetic and pharmacodynamic assessments; similar to a recent report, 7 but excluding participants from one trial in which the background medication could freely be adjusted. Data for efficacy responses (HbA1c and body weight) comprised all participants exposed to at least one semaglutide dose with at least two valid pharmacokinetic observations, and participants treated with placebo. The safety analysis dataset (used for analyses of pulse rate, calcitonin and gastrointestinal [GI] adverse events
[AEs]) comprised all participants in the data file for efficacy response with at least one valid pharmacokinetic observation. Calcitonin was selected as a biomarker for C-cell activity and mass because of observed C-cell changes in rodents with GLP-1 receptor agonists (RAs) .
Response values at week 30 were used for analysis of changes in HbA1c and body weight; pulse rate and calcitonin changes were analysed until end-of-treatment (Table S1 ). Estimates from a mixed model for repeated measurement analysis were used to impute missing response values (HbA1c: 10.3%, body weight: 9.6%, pulse rate: 16.6%
of values imputed). For analysis of GI AEs (nausea, vomiting, diarrhoea and constipation), all events reported from baseline until week 30 were included in the analysis. For calcitonin, only participants with a normal baseline value and post-baseline data were included in the analysis.
No imputations were applied for GI AEs or calcitonin. A sensitivity analysis with exclusion of imputed response values showed only minor impact on the estimates for the variables.
Average semaglutide steady-state concentrations (C avg ) were derived from the individual estimates of clearance following subcutaneous injection in a population-pharmacokinetic analysis 7 and were used as a measure of exposure. For the analyses of HbA1c, body weight, pulse rate, calcitonin and GI AEs, the C avg value at the randomized maintenance dose was used.
| Blood sampling and semaglutide exposure
In the trials, 4-weekly dose escalations of semaglutide (0.25, 0.5, Semaglutide plasma concentrations were measured using a validated liquid chromatography-tandem mass spectrometry assay (Celerion Inc., Fehraltorf, Switzerland), as previously described. 5 The lower limit of quantification was 0.729 nmol/L. Samples below the lower limit of quantification were excluded from the analysis. HbA1c was assayed in plasma using ion-exchange high-pressure liquid chromatography (assay range 3.1%-18.5%). Calcitonin was assayed in serum using a chemiluminescent immunometric method (assay range 2.0-2000 pg/mL).
| Exposure-response analyses
Exposure-response relationships were visualized using quantile plots with model prediction overlays. The models included covariates that influence exposure and/or response. For each variable of interest, participants treated with semaglutide were divided into six quantiles based on their exposure values; with quantile 1 representing the lowest exposure and quantile 6, the highest, with an additional quantile for participants treated with placebo that was assigned a value of 0 exposure. If other stratifications were included in a plot, 3 or 4 exposure quantiles were used instead. For each exposure quantile, we plotted the mean and 95% confidence interval (CI) for the response variable of interest against the median semaglutide concentration (C avg ). The modelling approach has been described in detail elsewhere.
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The software program R (ver. 2.1.4.2, R Foundation; Revolution Analytics, Mountain View, California, ver. 6) was used for data file processing, explorative data analysis, plotting and exposure-response analyses.
| Analysis of change from baseline in HbA1c vs exposure
The exposure-response model for HbA1c change from baseline until week 30 was developed as follows.
Initially, the presence of a significant slope was tested using a linear model. It was confirmed that the slope was significantly different from zero, hence an E max model was developed as described below.
Pre-selected covariates were included in the base model: trial; sex; age group; baseline body weight; and baseline HbA1c: was the effect of HbA1c at baseline centred on 8%, E weight was the effect of body weight centred on 85 kg, E sex was the effects of male sex, and E age ≥ 65 was the effect of age group.
Interaction effects were also tested for the covariates sex, Asian, black or African American, Japanese and Hispanic or Latino. No clear effects were found; therefore, these covariates were not included.
| Analysis of change from baseline in body weight
The exposure-response model for body weight change from baseline to week 30 in percentage was developed as follows.
A test of slope was conducted for the linear model excluding placebo data and including trial, sex, age group, baseline body weight and baseline HbA1c as covariates. The test confirmed a significant slope.
An E max model was estimated for body weight, but the EC 50 was estimated to be a very high value, therefore no further development took place. This finding was in accordance with the graphical inspection of the data which indicated a linear relationship for semaglutide.
The linear model was developed further by testing covariate effects previously known to be relevant for body weight:
1. A sex-C avg interaction covariate was found to be significant and was included in the model.
2. Additional covariates on the exposure-response slope were explored. None of these were found to have a significant effect (data not shown) and were therefore not included in the model. The final linear model had the same covariates as for HbA1c:
where Isex was the interaction effect of sex on the slope; the other terms were as defined above.
The exposure-response models for HbA1c responders, calcitonin and pulse rate are provided in Appendix S1.
| Analysis of GI AEs vs time and exposure
In the development of the exposure-response models for GI AEs, a test of slope was conducted for the logistic regression models excluding placebo data and including trial, sex, age group, escalation regimen and Japanese race as covariates. A covariate factor for dose escalation was included to adjust for the different escalation procedures for the 1.0 mg dose level, which was escalated in two steps, and the 0.5 mg dose level, which was escalated in one step. Furthermore, because differences in the GI AE profile were observed between Japanese and non-Japanese participants, an additional covariate factor (E Japanese ) was included. Baseline body weight was highly correlated to exposure within each dose group and could not be estimated accurately for GI AEs.
In the final model, the proportions of participants with reported nausea, vomiting, diarrhoea and constipation were analysed graphi- Nausea and constipation:
Vomiting and diarrhoea:
where p(GI event ) was the probability of reporting a GI event during 30 weeks of semaglutide treatment; α described the relationship of event probability to exposure; and E Japanese , E sex , E age ≥ 65 , E trial and E escalation were covariate effects of race, sex, age, trial and dose escalation, respectively. The E escalation factor was introduced to adjust for the different escalation procedures for the 1.0 mg dose level (escalated in three steps via 0.25 and 0.5 mg), and the 0.5 mg dose level (escalated in two steps via 0.25 mg). The E Japanese factor was also included, as differences in the GI AE profile were observed between Japanese and non-Japanese participants. The additional influence of baseline HbA1c and body weight was not included in the final model because of only minor improvements of the model fit.
3 | RESULTS
| Participant characteristics
The population included in the exposure-response analyses covered a Table S2 ).
| Semaglutide exposure and HbA1c reduction
The exposure-response relationship between semaglutide exposure and HbA1c change from baseline to week 30 is shown in Figure 1 . The exposure-response model for HbA1c was evaluated by assessing standard goodness-of-fit plots, which were found to be acceptable ( Figure S3 ).
| Semaglutide exposure and body weight reduction
The exposure-response relationship between semaglutide exposure and change from baseline to week 30 in body weight is shown in Figure 2 . Body weight loss increased linearly with increasing semaglutide exposure, with a relative weight loss from baseline of~6.5% for the highest exposure quantile and a predicted weight loss of~8% for participants with exposure at the upper end of the exposure range ( Figure 2A ). The characteristics of the exposure-response relationships were similar in each trial (data not shown). When stratifying by sex, body weight loss was greater in women than in men, with a steeper slope vs exposure for women compared to men ( Figure 2B ).
Standard goodness-of-fit plots were also used to evaluate the exposure-response model for body weight and were found to be acceptable ( Figure S4 ).
| Exploration of HbA1c and body weight responses across populations
For the exposure-response relationship for HbA1c and body weight, the most influential covariate factors were baseline HbA1c and baseline body weight and, moreover, body weight loss was influenced by sex. Therefore, we conducted additional subgroup analyses for these (Table 1) .
We observed greater effects of semaglutide on HbA1c in the 10% of participants with the lowest body weight than in those with the 10% highest weight. Nevertheless, in the heaviest participants a substantial effect on HbA1c and body weight was observed with semaglutide 0.5 mg, despite the lower exposure.
| Semaglutide exposure and safety outcomes
An increase from baseline to end-of-trial in mean resting pulse rate of 2−4 bpm was observed with semaglutide treatment ( Figure S5A ).
The exposure-response relationship for pulse rate was described by a linear model with a slope not significantly different from 0, indicating that the increase in pulse rate was exposure-independent in the range of semaglutide exposures achieved with doses of 0.5 and 1.0 mg.
The proportion of participants with serum calcitonin concentrations above the reference ranges at any time after baseline until endof-treatment is shown in Figure S5B and was low overall: 36 of 1395 participants (2.6%). The analysis suggested that elevated calcitonin levels were independent of exposure in the investigated range of semaglutide exposures achieved with 0.5 and 1.0 mg semaglutide, with no effect of semaglutide vs placebo. Figure 3A shows the proportion of participants reporting nausea, the most frequent GI event, over the 30-week period vs time. The proportion of participants reporting events of nausea increased following each dose escalation: at week 4 and at week 8 ( Figure 3A ).
More participants with high exposure than participants with low exposure within the same dose group reported nausea. The proportion of participants reporting nausea started to decline after 8 to 12 weeks of treatment, depending on the allocated dose level, indicating tolerance development over time.
Nausea tolerance development is further illustrated in Figure 3B . The exposure-response relationship at week 1 indicated an increase in nausea vs exposure. While the proportion of participants reporting nausea was higher with high vs low exposure during the first 4 weeks, the proportion remained below~7%, also for participants with high exposure ( Figure 3A) . During subsequent weeks, the slope of the exposure-response curve became right-shifted and flatter. The concentration of semaglutide estimated to be tolerated without nausea by 95% of participants increased from <5 to >30 nmol/L from week 1 to week 30 ( Figure 3B ). The sensitivity analyses for nausea using LOCF imputation or the completer population supported the main results, with similar evidence of tolerance development over time (data not shown).
The proportion of participants with nausea at a given exposure level was slightly lower at the semaglutide 1.0 mg maintenance dose (escalated in 3 steps) compared with 0.5 mg (2 steps; Figure 3C ).
Nausea was more frequently reported in women than in men across the range of exposures ( Figure 3D ). The proportions of participants reporting nausea was lower in SUSTAIN−Japan than in the other trials, with smaller changes across the exposure range (data not shown).
As observed with nausea, the exposure-response analysis of vomiting showed an increased proportion of participants with events and number of events with increasing exposure (data not shown), with an indication of tolerance development and similar differences between men/women and among trials. In contrast, the proportion of participants reporting diarrhoea and constipation was largely independent of exposure and with limited tolerance development (not shown).
| DISCUSSION
The exposure-response analyses revealed clinically relevant reduc- A linear relationship between semaglutide exposure and body weight loss was observed, indicating that greater weight loss was achieved with higher exposures. Although the lightest participants achieved a higher exposure than that observed in heavy participants, they would be expected to also benefit from increasing the dose. In fact, weight loss benefits would be expected to be greater in lighter participants because the absolute increase in exposure was greatest for these participants. The steeper slope vs exposure for women was also seen with liraglutide; 20 the reason for this is currently unknown.
Gastrointestinal AEs are a well-known consequence of GLP-1RA treatment. [21] [22] [23] The exposure-response profiles for nausea at early time points were steep, consistent with the higher nausea incidence reported in the phase II trial after treatment with 0.8 mg semaglutide without dose escalation. 6 This regimen led to higher exposure at earlier time points, compared with phase III trials. In the phase III trials, in which semaglutide 1.0 mg was achieved by dose escalation, the exposure-response profiles for nausea at comparable exposures as in the phase II trial (without dose escalation) were less steep, emphasizing the benefit of dose escalation as tolerance develops. The higher incidences of nausea and vomiting reported by women than men across the range of exposures were also observed with other GLP-1RAs. 24 The increased pulse rate from baseline to end-of-trial compared with placebo has been seen previously with semaglutide [8] [9] [10] [11] 15, 16 and other GLP-1RAs, 25 although there is no evidence of an increased cardiovascular risk. 16, 26 While the clinical significance of the increase remains unknown, the presence of GLP-1 receptors on the sinoatrial node may indicate a direct chronotropic effect. 27 In the present analysis, there was no evidence of an exposure-pulse rate relationship at the exposure levels associated with 0.5 and 1.0 mg semaglutide, consistent with results for liraglutide. 20 There was also no evidence of increased calcitonin levels with increasing semaglutide exposure. No evidence of increased calcitonin concentrations was likewise found with liraglutide compared with placebo after 3 years. 28 Limitations of the present study include that maintenance doses were limited to 0.5 and 1.0 mg semaglutide and thus did not allow an assessment of the full exposure-response relationships for body weight. The applied exposure-response models were limited to response data at specific time points after the start of treatment and are therefore not suitable for evaluating changes in treatment responses over time. Furthermore, for the exposure-response analysis of GI AEs, the average steady-state concentration with the maintenance dose was used as a predictor for all events reported during the trials, including events at earlier time points during dose escalation;
however, as the estimated exposure was based on individual drug clearance, this estimate would probably also reflect the individual exposure level during the dose escalation. Additional model analyses are needed to elucidate the complete picture for the tolerance development and nausea incidence over time.
Whereas the primary purpose of these analyses was to provide information supporting the relevance of the two investigated dose levels in the adult T2DM programme, the analyses also offer a hypothesis-generating basis for evaluating dose selection in other indications, such as weight management and non-alcoholic steatohepatitis, and are an important reference for evaluating paediatric data.
In summary, determining the optimal treatment dose with the optimal benefit-risk ratio is complex and exposure-response analyses can assist the decision-making process. In this exposure-response analysis, all subgroups obtained a clinically relevant benefit with semaglutide 0.5 mg and an additional benefit with the 1.0 mg semaglutide dose. Increasing the dose was shown to provide a modest increase in nausea and other GI side effects, which can be mitigated by dose escalation. Neither pulse rate nor increased calcitonin concentrations were dependent on the exposure level. The exposure-response analysis therefore supports the use of the proposed therapeutic doses of 0.5 and 1.0 mg semaglutide across all subgroups for improving glycaemic control, depending on individual need for HbA1c reduction.
